

# Carlos V P Jardim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7384403/publications.pdf>

Version: 2024-02-01

51  
papers

1,175  
citations

394390

19  
h-index

395678

33  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1286  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis. <i>Circulation</i> , 2009, 119, 1518-1523.	1.6	176
2	Cancer-associated thrombosis: the when, how and why. <i>European Respiratory Review</i> , 2019, 28, 180119.	7.1	160
3	NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. <i>Respiratory Medicine</i> , 2007, 101, 69-75.	2.9	65
4	Pulmonary Arterial Hypertension in the Southern Hemisphere. <i>Chest</i> , 2015, 147, 495-501.	0.8	54
5	The Role of Target Therapies in Schistosomiasis-Associated Pulmonary Arterial Hypertension. <i>Chest</i> , 2012, 141, 923-928.	0.8	48
6	Skeletal Muscle Abnormalities in Pulmonary Arterial Hypertension. <i>PLoS ONE</i> , 2014, 9, e114101.	2.5	41
7	Acute vasodilator test in pulmonary arterial hypertension: Evaluation of two response criteria. <i>Vascular Pharmacology</i> , 2005, 43, 143-147.	2.1	40
8	Quality of life as a prognostic marker in pulmonary arterial hypertension. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 130.	2.4	40
9	Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. <i>Current Medical Research and Opinion</i> , 2005, 21, 907-911.	1.9	36
10	Pulmonary hypertension in lymphangiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 74.	2.7	34
11	Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension. <i>Journal of Infection</i> , 2014, 68, 90-98.	3.3	33
12	Safety and efficacy of sitaxsentan 50 and 100Âmg in patients with pulmonary arterial hypertension. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012, 25, 33-39.	2.6	32
13	ValidaÃ§Ã£o de um protocolo para o teste de caminhada de seis minutos em esteira para avaliaÃ§Ã£o de pacientes com hipertensÃ£o arterial pulmonar. <i>Jornal Brasileiro De Pneumologia</i> , 2009, 35, 423-430.	0.7	29
14	II Guidelines for perioperative evaluation of the Brazilian Society of Cardiology. <i>Arquivos Brasileiros De Cardiologia</i> , 2011, 96, 1-68.	0.8	29
15	DiagnÃ³stico e tratamento da hipertensÃ£o pulmonar: uma atualizaÃ§Ã£o. <i>Jornal Brasileiro De Pneumologia</i> , 2010, 36, 795-811.	0.7	26
16	Other Causes of PAH (Schistosomiasis, Porto-Pulmonary Hypertension and Hemolysis-Associated) <i>Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50</i>	2.1	25
17	II Diretriz de AvaliaÃ§Ã£o PerioperatÃ³ria da Sociedade Brasileira de Cardiologia. <i>Arquivos Brasileiros De Cardiologia</i> , 2011, 96, 1-68.	0.8	23
18	3rd GUIDELINE FOR PERIOPERATIVE CARDIOVASCULAR EVALUATION OF THE BRAZILIAN SOCIETY OF CARDIOLOGY. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 109, 1-104.	0.8	21

#	ARTICLE	IF	CITATIONS
19	Use of direct oral anticoagulants for chronic thromboembolic pulmonary hypertension. <i>Clinics</i> , 2018, 73, e216.	1.5	19
20	Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2015, 15, 118.	2.0	16
21	Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. <i>European Respiratory Journal</i> , 2018, 51, 1800307.	6.7	16
22	Tadalafil para o tratamento da hipertensão arterial pulmonar idiopática. <i>Arquivos Brasileiros De Cardiologia</i> , 2006, 87, e195-e197.	0.8	12
23	Idiopathic Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 560-567.	2.1	11
24	Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment. <i>PLoS ONE</i> , 2020, 15, e0233063.	2.5	10
25	The Need for National Registries in Rare Diseases. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 228-228.	5.6	9
26	Reperfusion in acute pulmonary thromboembolism. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 237-243.	0.7	9
27	Corticoide sistêmico como tratamento de primeira linha da hipertensão pulmonar secundária a síndrome POEMS. <i>Jornal Brasileiro De Pneumologia</i> , 2009, 35, 804-808.	0.7	9
28	Biomarkers and Prognostic Indicators in Pulmonary Arterial Hypertension. <i>Current Hypertension Reports</i> , 2015, 17, 556.	3.5	8
29	Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think. <i>Jornal Brasileiro De Pneumologia</i> , 2019, 45, e20180297.	0.7	7
30	The Role of NT-proBNP as a Prognostic Marker in Pulmonary Hypertension. <i>Chest</i> , 2006, 130, 1627.	0.8	6
31	Electrical impedance tomography in pulmonary arterial hypertension. <i>PLoS ONE</i> , 2021, 16, e0248214.	2.5	6
32	Atualização no Tratamento da Hipertensão Arterial Pulmonar. <i>Arquivos Brasileiros De Cardiologia</i> , 2021, 117, 750-764.	0.8	6
33	O papel dos exames de imagem na avaliação da circulação pulmonar. <i>Jornal Brasileiro De Pneumologia</i> , 2011, 37, 389-403.	0.7	5
34	Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-3.	1.7	4
35	Goal-oriented treatment of pulmonary arterial hypertension. <i>Current Opinion in Pulmonary Medicine</i> , 2014, 20, 409-413.	2.6	3
36	The global view. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 391-397.	2.6	3

#	ARTICLE	IF	CITATIONS
37	Lung Cavities in Chronic Thromboembolic Pulmonary Hypertension. Clinics, 2020, 75, e1373.	1.5	3
38	The importance of the World Symposium on Pulmonary Hypertension. Jornal Brasileiro De Pneumologia, 2018, 44, 173-174.	0.7	3
39	Brazilian Thoracic Society recommendations for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension. Jornal Brasileiro De Pneumologia, 2020, 46, e20200204-e20200204.	0.7	3
40	Schistosomiasis and Pulmonary Hypertension. Progress in Respiratory Research, 2012, , 143-148.	0.1	2
41	Aortopulmonary Window: A Rare Cause of Pulmonary Hypertension. Respiration, 2008, 76, 351-352.	2.6	1
42	Letter by Dias et al Regarding Article, "Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary Thromboendarterectomy". Circulation, 2010, 122, e1.	1.6	1
43	Epidemiology and Disease Classification of Pulmonary Hypertension. Respiratory Medicine, 2015, , 21-35.	0.1	1
44	The Role Of Target-Therapies In Schistosomiasis-Associated Pulmonary Arterial Hypertension. , 2011, , .		0
45	Comparative Analysis Of The Immunopathology In Idiopathic Versus Schistosomiasis-Associated Pulmonary Arterial Hypertension. , 2011, , .		0
46	Biomarkers in Pulmonary Arterial Hypertension. Progress in Respiratory Research, 2012, , 59-64.	0.1	0
47	Resolução do "shunt" direita-esquerda após uso do sildenafil como tratamento de hipertensão pulmonar primária. Jornal De Pneumologia, 2003, 29, 305-308.	0.1	0
48	Schistosomiasis and others in group 5. , 2011, , 491-499.		0
49	Prognostic value of predicted 6MWD in PAH. , 2015, , .		0
50	The use of new anticoagulants in CTEPH. , 2017, , .		0
51	Effect of targeted therapies on survival of schistosomiasis associated pulmonary arterial hypertension. , 2017, , .		0